Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2019

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms FOURIER; PROFICIO
  • Sponsors Amgen
  • Most Recent Events

    • 18 Jun 2019 Results published in the Journal of the American College of Cardiology
    • 18 Mar 2019 Results assessing efficacy and safety of evolocumab use among participants of Asian versus other backgrounds presented at the 68th Annual Scientific Session of the American College of Cardiology
    • 24 Jan 2019 According to an Amgen media release, based on the data of this study, the National Medical Products Administration (NMPA) has approved Repatha (evolocumab), as a new indication in China, for adults with atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top